Amgen Plays Both Sides As It Builds Out Inflammation Biosimilars
Remicade Biosimilar Avsola Launched In July
Amgen has reiterated the strength and capabilities of its dual commercial model by suggesting it will replicate its strategy for oncology biosimilars for its burgeoning inflammation product portfolio.
You may also be interested in...
Amgen’s management took a deep dive into biosimilar market dynamics during the company’s third-quarter earnings call, as the California-based biotech continued to enjoy success for biosimilars in the US and Europe.
Amgen has filed to settle on undisclosed terms patent-infringement litigation involving both its Kanjinti and Mvasi biosimilars, having previously seen originator Genentech fail multiple times to block commercial sales of the products that were launched ‘at risk’.
With its own interests in the branded eye-disease space, Regeneron has commented on ranibizumab biosimilar sponsor Biogen’s fortunes during a recent conference.